Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify [email protected] if there are concerns regarding accuracy of the transcription.
CLEVELAND, Feb. 21, 2022 /PRNewswire/ -- NovelMed Therapeutics, Inc. announced today interim positive results from a First-in-Human Phase I clinical trial of its complement blocker monoclonal anti-Bb ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback